211 related articles for article (PubMed ID: 31545408)
1. Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral T‑cell lymphoma expressing the ITK‑SYK fusion gene.
Zhang LL; Pan HX; Wang YX; Guo T; Liu L
Int J Oncol; 2019 Nov; 55(5):1077-1089. PubMed ID: 31545408
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
Ando S; Kawada JI; Watanabe T; Suzuki M; Sato Y; Torii Y; Asai M; Goshima F; Murata T; Shimizu N; Ito Y; Kimura H
Oncotarget; 2016 Nov; 7(47):76793-76805. PubMed ID: 27732937
[TBL] [Abstract][Full Text] [Related]
3. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
4. Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression.
Fathi NN; Mohammad DK; Görgens A; Andaloussi SE; Zain R; Nore BF; Smith CIE
Biochem Biophys Res Commun; 2018 Oct; 504(4):749-752. PubMed ID: 30217447
[TBL] [Abstract][Full Text] [Related]
5. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
[TBL] [Abstract][Full Text] [Related]
6. Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2018 Oct; 53(4):1681-1690. PubMed ID: 30066853
[TBL] [Abstract][Full Text] [Related]
7. [The STAT5 signaling in the expression of alpha-subunit of interleukin-2 receptor in human blood lymphocytes].
Mitiushova EV; Shatrova AN; Zenin VV; Aksenov ND; Marakhova II
Tsitologiia; 2013; 55(6):421-9. PubMed ID: 25509109
[TBL] [Abstract][Full Text] [Related]
8. Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells.
Kirken RA; Erwin RA; Wang L; Wang Y; Rui H; Farrar WL
J Immunol; 2000 Nov; 165(9):5097-104. PubMed ID: 11046040
[TBL] [Abstract][Full Text] [Related]
9. The molecular mechanism of curcumol on inducing cell growth arrest and apoptosis in Jurkat cells, a model of CD4⁺ T cells.
Wang H; Wang Y; Jiang X; Wang Z; Zhong B; Fang Y
Int Immunopharmacol; 2014 Aug; 21(2):375-82. PubMed ID: 24877754
[TBL] [Abstract][Full Text] [Related]
10. The lymphoma-associated fusion tyrosine kinase ITK-SYK requires pleckstrin homology domain-mediated membrane localization for activation and cellular transformation.
Rigby S; Huang Y; Streubel B; Chott A; Du MQ; Turner SD; Bacon CM
J Biol Chem; 2009 Sep; 284(39):26871-81. PubMed ID: 19535334
[TBL] [Abstract][Full Text] [Related]
11. The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma.
Pechloff K; Holch J; Ferch U; Schweneker M; Brunner K; Kremer M; Sparwasser T; Quintanilla-Martinez L; Zimber-Strobl U; Streubel B; Gewies A; Peschel C; Ruland J
J Exp Med; 2010 May; 207(5):1031-44. PubMed ID: 20439541
[TBL] [Abstract][Full Text] [Related]
12. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.
Zhang Q; Nowak I; Vonderheid EC; Rook AH; Kadin ME; Nowell PC; Shaw LM; Wasik MA
Proc Natl Acad Sci U S A; 1996 Aug; 93(17):9148-53. PubMed ID: 8799169
[TBL] [Abstract][Full Text] [Related]
13. BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3.
Nakayama J; Yamamoto M; Hayashi K; Satoh H; Bundo K; Kubo M; Goitsuka R; Farrar MA; Kitamura D
Blood; 2009 Feb; 113(7):1483-92. PubMed ID: 19047679
[TBL] [Abstract][Full Text] [Related]
14. Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice.
Sprissler C; Belenki D; Maurer H; Aumann K; Pfeifer D; Klein C; Müller TA; Kissel S; Hülsdünker J; Alexandrovski J; Brummer T; Jumaa H; Duyster J; Dierks C
Blood Cancer J; 2014 Aug; 4(8):e240. PubMed ID: 25148222
[TBL] [Abstract][Full Text] [Related]
15. Protein phosphatase 2A regulates interleukin-2 receptor complex formation and JAK3/STAT5 activation.
Ross JA; Cheng H; Nagy ZS; Frost JA; Kirken RA
J Biol Chem; 2010 Feb; 285(6):3582-3591. PubMed ID: 19923221
[TBL] [Abstract][Full Text] [Related]
16. t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5.
Ehrentraut S; Nagel S; Scherr ME; Schneider B; Quentmeier H; Geffers R; Kaufmann M; Meyer C; Prochorec-Sobieszek M; Ketterling RP; Knudson RA; Feldman AL; Kadin ME; Drexler HG; MacLeod RA
PLoS One; 2013; 8(1):e53767. PubMed ID: 23372669
[TBL] [Abstract][Full Text] [Related]
17. Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.
Agarwal A; MacKenzie RJ; Eide CA; Davare MA; Watanabe-Smith K; Tognon CE; Mongoue-Tchokote S; Park B; Braziel RM; Tyner JW; Druker BJ
Oncogene; 2015 Jun; 34(23):2991-9. PubMed ID: 25109334
[TBL] [Abstract][Full Text] [Related]
18. Uncoupling JAK3 activation induces apoptosis in human lymphoid cancer cells via regulating critical survival pathways.
Nagy ZS; Ross JA; Rodriguez G; Bader J; Dimmock J; Kirken RA
FEBS Lett; 2010 Apr; 584(8):1515-20. PubMed ID: 20211620
[TBL] [Abstract][Full Text] [Related]
19. NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3.
Kim BH; Jee JG; Yin CH; Sandoval C; Jayabose S; Kitamura D; Bach EA; Baeg GH
Mol Cancer; 2010 Feb; 9():36. PubMed ID: 20149240
[TBL] [Abstract][Full Text] [Related]
20. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.
Bouchekioua A; Scourzic L; de Wever O; Zhang Y; Cervera P; Aline-Fardin A; Mercher T; Gaulard P; Nyga R; Jeziorowska D; Douay L; Vainchenker W; Louache F; Gespach C; Solary E; Coppo P
Leukemia; 2014 Feb; 28(2):338-48. PubMed ID: 23689514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
